npj Precision Oncology (Mar 2023)

Homologous recombination deficiency signatures in gastrointestinal and thoracic cancers correlate with platinum therapy duration

  • Erica S. Tsang,
  • Veronika Csizmok,
  • Laura M. Williamson,
  • Erin Pleasance,
  • James T. Topham,
  • Joanna M. Karasinska,
  • Emma Titmuss,
  • Intan Schrader,
  • Stephen Yip,
  • Basile Tessier-Cloutier,
  • Karen Mungall,
  • Tony Ng,
  • Sophie Sun,
  • Howard J. Lim,
  • Jonathan M. Loree,
  • Janessa Laskin,
  • Marco A. Marra,
  • Steven J. M. Jones,
  • David F. Schaeffer,
  • Daniel J. Renouf

DOI
https://doi.org/10.1038/s41698-023-00368-x
Journal volume & issue
Vol. 7, no. 1
pp. 1 – 12

Abstract

Read online

Abstract There is emerging evidence about the predictive role of homologous recombination deficiency (HRD), but this is less defined in gastrointestinal (GI) and thoracic malignancies. We reviewed whole genome (WGS) and transcriptomic (RNA-Seq) data from advanced GI and thoracic cancers in the Personalized OncoGenomics trial (NCT02155621) to evaluate HRD scores and single base substitution (SBS)3, which is associated with BRCA1/2 mutations and potentially predictive of defective HRD. HRD scores were calculated by sum of loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions scores. Regression analyses examined the association between HRD and time to progression on platinum (TTPp). We included 223 patients with GI (n = 154) or thoracic (n = 69) malignancies. TTPp was associated with SBS3 (p < 0.01) but not HRD score in patients with GI malignancies, whereas neither was associated with TTPp in thoracic malignancies. Tumors with gBRCA1/2 mutations and a somatic second alteration exhibited high SBS3 and HRD scores, but these signatures were also present in several tumors with germline but no somatic second alterations, suggesting silencing of the wild-type allele or BRCA1/2 haploinsufficiency. Biallelic inactivation of an HR gene, including loss of XRCC2 and BARD1, was identified in BRCA1/2 wild-type HRD tumors and these patients had prolonged response to platinum. Thoracic cases with high HRD score were associated with high RECQL5 expression (p ≤ 0.025), indicating another potential mechanism of HRD. SBS3 was more strongly associated with TTPp in patients with GI malignancies and may be complementary to using HRD and BRCA status in identifying patients who benefit from platinum therapy.